Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating
Goldman Sachs Cuts Alnylam Pharma Stock to Neutral Following HELIOS-B Study Update
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $870, Maintains Hold Rating
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1020
Regeneron Pharmaceuticals Analyst Ratings
RBC Downgrades Nevro to Sector Perform, Cites Salesforce Turnaround
RBC Capital Upgrades Regeneron Pharmaceuticals to Outperform, Announces $1076 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $850 Price Target
Regeneron Pharmaceuticals Analyst Ratings
RBC Raises Price Target on Regeneron Pharmaceuticals to $884 From $837, Keeps Sector Perform Rating
Regeneron Pharmaceuticals Analyst Ratings
Morgan Stanley Lifts Price Target on Regeneron Pharmaceuticals to $941 From $914, Keeps Overweight Rating
No Data